Seroatlas · Human Serome Atlas

ACSM5

Acyl-coenzyme A synthetase ACSM5, mitochondrial

Also known as: ACSM5_HUMAN, FLJ20581

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6NUN0
Gene: ACSM5
Ensembl: ENSG00000183549
Chromosome: 16
Canonical length: 579 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Vesicles

OverviewNCBI Gene

Predicted to enable fatty acid ligase activity and fatty-acyl-CoA synthase activity. Predicted to be involved in acyl-CoA metabolic process and fatty acid biosynthetic process. Located in mitochondrion. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

579 residues, UniProt reviewed canonical sequence.

>Q6NUN0|ACSM5
     1  MRPWLRHLVL QALRNSRAFC GSHGKPAPLP VPQKIVATWE AISLGRQLVP EYFNFAHDVL
    61  DVWSRLEEAG HRPPNPAFWW VNGTGAEIKW SFEELGKQSR KAANVLGGAC GLQPGDRMML
   121  VLPRLPEWWL VSVACMRTGT VMIPGVTQLT EKDLKYRLQA SRAKSIITSD SLAPRVDAIS
   181  AECPSLQTKL LVSDSSRPGW LNFRELLREA STEHNCMRTK SRDPLAIYFT SGTTGAPKMV
   241  EHSQSSYGLG FVASGRRWVA LTESDIFWNT TDTGWVKAAW TLFSAWPNGS CIFVHELPRV
   301  DAKVILNTLS KFPITTLCCV PTIFRLLVQE DLTRYQFQSL RHCLTGGEAL NPDVREKWKH
   361  QTGVELYEGY GQSETVVICA NPKGMKIKSG SMGKASPPYD VQIVDDEGNV LPPGEEGNVA
   421  VRIRPTRPFC FFNCYLDNPE KTAASEQGDF YITGDRARMD KDGYFWFMGR NDDVINSSSY
   481  RIGPVEVESA LAEHPAVLES AVVSSPDPIR GEVVKAFIVL TPAYSSHDPE ALTRELQEHV
   541  KRVTAPYKYP RKVAFVSELP KTVSGKIQRS KLRSQEWGK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ACSM5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.24
Highest tissue expression: 259 nTPM

Expression across tissuesHPA

Tissue

liver: 259 nTPM
adipose tissue: 24 nTPM
kidney: 24 nTPM
skeletal muscle: 13 nTPM
breast: 11 nTPM
midbrain: 9 nTPM

Single-cell type

hepatocytes: 308 nCPM
microglia: 73 nCPM
myosatellite cells: 62 nCPM
adipocytes: 61 nCPM
epididymal efferent duct absorptive cells: 42 nCPM
proximal tubule cells: 39 nCPM

Immune cell

myeloid DC: 0.9 nTPM
classical monocyte: 0.8 nTPM
intermediate monocyte: 0.5 nTPM
non-classical monocyte: 0.4 nTPM
basophil: 0.1 nTPM
total PBMC: 0.1 nTPM

Brain region

thalamus: 15 nTPM
white matter: 15 nTPM
hypothalamus: 15 nTPM
amygdala: 13 nTPM
medulla oblongata: 12 nTPM
midbrain: 12 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.26
gnomAD pLI: 0
gnomAD missense Z: -0.62
DepMap mean gene effect: 0
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ACSM5 as an antibody target. Whether an autoantibody or antibody against ACSM5 could matter depends on whether native ACSM5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ACSM5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ACSM5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...